Sign In
Buy RCAR
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Contrasting Biofrontera (NASDAQ:BFRI) & RenovaCare (OTCMKTS:RCAR)
01:39am, Thursday, 19'th Feb 2026
RenovaCare (OTCMKTS:RCAR - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the
RenovaCare (OTCMKTS:RCAR) Stock Crosses Above 50 Day Moving Average – Time to Sell?
04:38am, Saturday, 20'th Dec 2025
RenovaCare Inc. (OTCMKTS:RCAR - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.00 and traded as high
RenovaCare Inc. Provides Notice of Proposed Derivative Settlement to All Record Holders and Beneficial Owners of RenovaCare, Inc.
05:35pm, Wednesday, 12'th Feb 2025
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--RenovaCare Inc. (OTC: RCAR): IN THE EIGHTH JUDICIAL DISTRICT COURT OF THE STATE OF NEVADA IN AND FOR CLARK COUNTY PETER RIGSBY, Derivatively on Behalf of RENOVACARE
NEWARK, N.J., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP announces that the United States District Court for the District of New Jersey has approved the following announcement o
RenovaCare Announces Termination of StemCell Systems R&D Agreement
10:06am, Tuesday, 03'rd May 2022
SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for th
SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating RenovaCare, Inc.
06:19pm, Thursday, 14'th Apr 2022
Wilmington, Delaware--(Newsfile Corp. - April 14, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of RenovaCare, Inc. (OTC Pink: RCAR) on behalf of sto
RenovaCare Announces Management Changes
08:30am, Thursday, 24'th Mar 2022
SCOTTSDALE, Ariz., March 24, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for
RenovaCare Provides Clinical and Corporate Update
03:35pm, Wednesday, 09'th Mar 2022
SCOTTSDALE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for
RM LAW Announces Investigation of RenovaCare, Inc.
12:30pm, Thursday, 03'rd Feb 2022
BERWYN, Pa. , Feb. 3, 2022 /PRNewswire/ -- RM LAW, P.C.
SHAREHOLDER ALERT: Robbins LLP Investigates RenovaCare, Inc. (RCAR) on Behalf of Investors
05:14pm, Tuesday, 28'th Dec 2021
SAN DIEGO--(BUSINESS WIRE)---- $RCAR #classaction--RenovaCare, Inc. (RCAR) Charged with Securities Fraud
NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against RenovaCare, Inc. (Other OTC: RCAR) on be
RenovaCare (OTCMKTS:RCAR) Stock Price Passes Below 50 Day Moving Average of $0.93
06:46pm, Friday, 17'th Dec 2021 Dakota Financial News
RenovaCare, Inc. (OTCMKTS:RCAR)s share price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.93 and traded as low as $0.76. RenovaCare shares last traded at $0.76, with a volume of 8,750 shares trading hands. The firms 50-day simple moving average is $0.92 and its []
Analyzing RenovaCare (RCAR) & The Competition
04:10am, Tuesday, 16'th Nov 2021 Dakota Financial News
RenovaCare (OTCMKTS: RCAR) is one of 192 public companies in the Surgical & medical instruments industry, but how does it weigh in compared to its competitors? We will compare RenovaCare to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability. Valuation and Earnings This table compares []
RenovaCare (RCAR) and Its Peers Head-To-Head Contrast
07:20am, Sunday, 14'th Nov 2021 Transcript Daily
RenovaCare (OTCMKTS: RCAR) is one of 192 publicly-traded companies in the Surgical & medical instruments industry, but how does it contrast to its peers? We will compare RenovaCare to similar companies based on the strength of its valuation, profitability, institutional ownership, dividends, analyst recommendations, earnings and risk. Insider and Institutional Ownership 51.0% of shares of []
SAN DIEGO, Sept. 16, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of RenovaCare, Inc. (OTC: RCAR) against certain of its officers and directors.
